InsiderTrades.com logo
New CBOE “special perk” helps traders target income every weekend
From DTI Trader   |   Ad
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Check out this training for the full story!

STX Insider Trading

Insider Ownership Percentage: 65.96%
Insider Buying (Last 12 Months): GBX 0
Insider Selling (Last 12 Months): £32,647.65

Shield Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Shield Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Shield Therapeutics Share Price & Price History

Current Price: GBX 6.25
Price Change: ▼ Price Decrease of -0.3 (-4.58%)
As of 12/8/2023 01:00 AM ET

This chart shows the closing price history over time for STX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

Shield Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/23/2022Greg MadisonInsiderSell466,395GBX 7£32,647.65
3/5/2021Hans-Peter HaslerInsiderBuy200,000GBX 38£76,000
3/3/2021Hans-Peter HaslerInsiderBuy200,000GBX 37£74,000
1/19/2021Tim WattsInsiderBuy100,000GBX 60£60,000
12/11/2020Tim WattsInsiderBuy100,000GBX 70£70,000
See Full Table
New CBOE “special perk” helps traders target income every weekend
From DTI Trader   |   Ad
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Check out this training for the full story!

SEC Filings (Institutional Ownership Changes) for Shield Therapeutics (LON:STX)

16.86% of Shield Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Shield Therapeutics logo
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Read More on Shield Therapeutics

Today's Range

Now: GBX 6.25
Low: 6.22
High: 6.57

50 Day Range

MA: GBX 6.30
Low: 5.80
High: 7.51

52 Week Range

Now: GBX 6.25
Low: 2.48
High: 12.85

Volume

2,398,951 shs

Average Volume

2,586,402 shs

Market Capitalization

£48.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Who are the company insiders with the largest holdings of Shield Therapeutics?

Shield Therapeutics' top insider shareholders include:
  1. Greg Madison (Insider)
Learn More about top insider investors at Shield Therapeutics.
Trading Experts Call It “The Perfect Tesla Trade”
From Wealthpress   |   Ad
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Click here for details,